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Abstract 
 
Background: Monitoring of emerging modes of drug consumption in France has identified 
new patterns of injection among youths with diverse social backgrounds, which may explain 
the persistence of high rates of hepatitis C virus infection. The circumstances surrounding the 
first injection have been poorly documented in the group of heavy drug users and in the 
context of the French opioid substitution treatment (OST) policy that provides expanded 
access to high-dosage buprenorphine (BHD) 
 
Methods: An Internet survey (Priminject) was conducted from October 2010 to March 2011 
with French drug users. Four time periods were compared based on critical dates throughout 
the implementation of the Harm Reduction Policy in France.  
 
Results: Compared with drug users who injected for the first time prior to 1995, the aspects of 
drug use for users who recently injected for the first time were as follows: (1) experimentation 
with miscellaneous drugs before the first injection; (2) an older age at the time of first 
injection; (3) heroin as the drug of choice for an individual’s first injection, notwithstanding 
the increased usage of stimulant drugs; (4) BHD did not appear to be a pathway to injection; 
and (5) an increased number of users who injected their first time alone, without the help or 
presence of another individual. 
 
Conclusion: The PrimInject study showed that there is a group of injection drug users that is 
larger than the group of injection drug users observed in previous studies; therefore, it is 
necessary to diversify programs to reach the entire spectrum of high-risk users. 
 
 
Keywords: Injection drug users, first injection episode, Internet study, France, 
buprenorphine, drugs uses. 
 
 
1. Introduction 
 
Since 2003, new diagnoses of HIV infection among drug users in France accounted for 2-3% 
of total cases, which amounts to approximately 70 cases per year (Le Vu et al., 2010). The 
prevalence rate decreased from 20% in the early 1990s to less than 10% in 2008 (Institut 
National de la Santé et de la Recherche Médicale - INSERM, 2010). These changes followed 
the introduction of free access to syringes in pharmacies (1987) and the implementation of 
syringe exchange programs, low-threshold services (1990), and opiate substitution treatments 
(1995). The hepatitis C virus (HCV) prevalence rate has remained very high (73%), however, 
and is not decreasing (Jauffret-Roustide et al., 2006). After a period of declining heroin use at 
the turn of the 21st century (Bello et al., 2004; Mitcallef et al., 2004, 2004; Palle et al., 2003), 
heroin has become more available (Cadet-Tairou et al., 2010), and the number of reported 
fatal overdoses has increased since 2004 (Centres d’Evaluation et d’Information sur la 
Pharmacodépendance – CEIP/ Décès en Relation avec l’Abus de Médicaments et de 
Substances - DRAMES, 2011).  
While injection drug use has continuously decreased in France (INSERM, 2010), field 
observations (Cadet-Tairou et al., 2010) have reflected the emergence of new groups of 
injection drug users and new patterns of substance abuse. Aside from underprivileged youths, 
new consumers belonging to diverse social backgrounds, such as users at rave/dance parties, 
use a wide spectrum of substances (hallucinogens, amphetamines, synthetic products, and 
cocaine and its derivatives), as observed by the network reporting emerging trends of drug use 
Cadet-Tairou et al., 2008; Girard et al., 2009). Heroin and other opiates, including opiate 
medicine (morphine-sulfate and high-dose buprenorphine (BHD)), are used occasionally or 
alternatively with other substances for their relaxing effects. Injection is one aspect of this 
behavior (Guichard et al., 2004; Guichard et al., 2006; Toufik et al., 2008).  
Therefore, the current harm reduction strategies may not be reaching these new groups of 
injectors and may thus lead to a higher prevalence of HVC, which is often acquired shortly 
after initiation into injection (Hagan et al., 2004; Maher et al., 2006; Maher et al., 2007; Roy 
et al., 2009; van den Berg et al., 2007; Bravo et al, 2012). 
Circumstances leading to injection in the new groups of injectors have not been well 
documented because the majority of studies have focused on the trajectory of long-term drug 
users, often the most marginalized, who are mainly recruited through drug dependence clinics 
or injection drug user networks (Crofts et al. 1996; Doherty et al., 2000; Frajzyngier et al., 
2007; Fuller et al., 2003; Goldsamt et al., 2010; Hadland et al., 2010; Kerr et al., 2007; 
Lankenau et al., 2010; Roy et al., 2003; Vidal-Trecan et al., 2002). The context of initiation 
for those who have injected only a few times or over a short period of time during their 
lifetime has been poorly described.  
To document the profile of new injectors, the PrimInject study was launched using the 
Internet to reach current or former injectors and obtain descriptions of their circumstances, 
behaviors, and exposure to blood-borne infections at initiation into injection drug use. The 
first injection is a particularly significant, generally unplanned event for individuals who are 
poorly informed regarding the techniques and risks of injecting (Doherty et al., 2000; 
Frajzyngier et al., 2007; Varescon et al., 2000).  
Long before 1995, buprenorphine in its analgesic form was used by injection drug users in 
France as a prescribed drug and as a street drug. In 1995, BHD was approved as an opiate 
substitution treatment to be prescribed by general practitioners (GPs) and delivered in 
community pharmacies for a maximum four-week period to allow a rapid scaling up of 
substitution therapy. Methadone was only available from drug treatment clinics with more 
restrictive regulations and was usually delivered without direct supervision after the initiation 
period. Since then, researchers have observed the transition to the street market and injection 
of tablets (Guichard et al., 2003; Guichard et al., 2006). Fieldworkers have repeatedly 
reported on the use of buprenorphine in individuals who have not used heroin previously, but 
the frequency of buprenorphine use has never been measured, even though it is a critical issue 
in implementing substitution treatment. Because the French regulation of substitution 
treatment is flexible, assessment of the role of buprenorphine in the initiation of injection is 
relevant to document the initiation process.  
The present paper focuses on the history of drug use and context of initiation among 
PrimInject respondents and emphasizes the period of initiation that corresponds with turning 
points in French drug policy over the last 30 years.  
 
2. Methods  
 
2.1. Population and design 
 
An advisory committee including professionals working in outreach programs, members of 
drug user organizations, and health administrations was set up to supervise the design of, 
promotion of, and tools used in the PrimInject study. Because the objective was to reach a 
socially diverse population of young people who recently started to inject drugs or who 
administered injections to themselves even once or a few times, the electronic music scene 
was especially considered. Indeed, field workers providing harm reduction services during 
electronic festivals are used to distribute syringes and injection equipment to festival 
participants and have reported an emerging use of injection in that population (Girard et al., 
2009) . This population, which is young, is not disadvantaged, and uses a wide variety of 
drugs during festivals, was targeted by using electronic music channels. The Internet is the 
main communication channel for youths and individuals participating in the electronic music 
scene and is considered effective to reach this small and hidden population (Velter, 2011; 
Frippiat et al., 2010), especially young drug users, and to capture ex-drug users or individuals 
who had only had sporadic experiences of drug injection. Use of the Internet also limits the 
selection effects of treatment or harm reduction services that often overrepresent the most 
marginalized population or the most severe substance use profiles. 
The promotion messages invited people to share their first injection experience by using an 
explicit URL www.shoot-premierefois.com. Various banners and prints using the party scene 
visual codes were first made available on selected websites and then through a large range of 
harm reduction programs and services (e.g., GPs, drug dependence clinics, community 
pharmacies, syringe exchange programs, and spaces for youth intervention) throughout the 
study period. Specific attention was given to outreach services, many of which were contacted 
individually to provide information about the study objectives and assurance of 
confidentiality. Some of these services provided an Internet option for individuals to fill out 
the questionnaire. 
Data collection took place from October 2010 to March 2011. Anyone could fill out the 
questionnaire, regardless of whether they had injected. Respondents who had never injected 
were directed toward a short version of the questionnaire that explored their attitudes and 
opinions of drug injection. There were no lower or upper age limits for opening the 
questionnaire. However, respondents under 15 years of age were redirected toward the end of 
the questionnaire after they documented their age. 
 
2.2. Questionnaire and variables of interest  
 
The questionnaire was developed and pretested by injection drug users. It covered current 
social status (e.g., level of education and employment), history of legal and illegal substance 
use, and the circumstances surrounding one’s first injection. An answer was required for each 
question (blank responses were not allowed).  
The variables of interest included the history of drug use before injection (use and age at first 
use of cannabis, ecstasy, cocaine, amphetamines, methamphetamine, ketamine, heroin, high-
dose buprenorphine, methadone, other opiates, and hallucinogens), year and place of the first 
injection (home or another private place, squat, street, outdoor location, and van/car), being 
alone at the time of first injection or not, injecting oneself or being assisted, the type of 
substances used, and the length of time (years, months, or days) between first use of the drug 
and injection. History of injection from initiation was documented with two variables: the 
total lifetime number of injections (only once, 2-5 times, 6-10 times, 11 times or more) and 
number of injections during the last month. 
 
2.3. Data analysis 
All participants who reported lifetime drug injection were included in the analysis. 
Respondents were categorized according to the time of their first injection. Cut-off values 
were defined based on key developments in the French Harm Reduction policy: (a) the period 
preceding the implementation of harm reduction policies (before 1987: no harm reduction); 
(b) the over-the-counter sale of syringes to drug users in pharmacies (starting in 1987: free 
access to syringes) and availability of sterile injection equipment through different facilities; 
(c) the 1996-2005 period, which is characterized by the implementation of substitution 
treatment (labeled as the Substitution era); and (d) the 2006-2010 period, which represents 
contemporary initiations (within five years of data collection, recent period) that are of 
particular interest for the current situation. In 2004 and 2005, the legal framework of harm 
reduction was reinforced by approval in the Public Health code as a pillar of French drug 
policy, and the components included as part of the harm reduction programs were detailed 
(decree of April 15, 2005).  
 
Mean, median, and proportion calculations were conducted for the whole sample and then for 
each group classified according to initiation of injection. Period comparisons were based on 
chi-square test and Fisher exact test for categorical variables and on variance analysis for the 
continuous variables. Trend tests were conducted using logistic regressions for proportions by 
dividing the time of initiation of injection in four categories, and trend tests were conducted 
using linear regressions for the means.  
 
 
 2.4. Ethical issues 
Data collection was approved by the French individual data protection authority (CNIL), and 
safeguards on confidentiality protection, anonymity of responses, and nonregistration of IP 
addresses were clearly stated on the home page of the survey.  
 
3. Results  
 
3.1. Subjects 
 
Among the 1,884 individuals who connected to the PrimInject URL, 1,318 (70%) started to 
fill the questionnaire. Among these individuals, 325 (25%) stopped answering questions 
before reaching the end of the section of the questionnaire that concerned the first injection 
and were removed, and 42 (3%) provided inconsistent answers. Most of these individuals 
discontinued completion or disconnected at the very beginning of the questionnaire, in the 
general information section. The individuals who dropped out were younger than those who 
continued (27.6 vs. 29.7, p<0.01) and were more often students. Among the 951 respondents, 
455 never injected (48%), 40 were living abroad (4%), and seven did not report the year of 
first injection. In total, 449 individuals were included in the final analysis. (Fig. 1) 
 
More than one-third of these respondents (36%) reported being introduced to the survey by 
outreach services, and 34% accessed the survey by surfing the Internet (through the banners 
of the associations’ websites). Of the respondents who accessed the survey through the 
Internet, 49% found the survey through the forum of a drug user self-support group. The 
remaining respondents received the information from treatment centers and health 
professionals working with drug users (drug dependence clinics, hospitals, and GPs). The 
youngest respondents (less than 25 years) (44%), students (82%), and respondents who had 
graduated from high school (46%) more often accessed the survey by surfing the internet 
(p<0.001), whereas men (41%), respondents aged more than 25 years (43%), respondents who 
had not graduated from high school (45%), and unemployed individuals (47%) were more 
likely to be recruited in harm reduction services (p<0.001). 
Of the 449 respondents, 64% were males, and 36% were females (Table 1). At the time of 
data collection, the mean age was 31.7 years old (range, 15-62); 36% of subjects were 
employed, 48% were unemployed, and 16% were students. Employment status reflected the 
respondents’ ages, but the percentage of unemployment was over 50% in the group who 
started injecting before 2005.  
Regarding the period of first injection, 71 individuals first injected before 1987; 68, during the 
“free syringe access” period (1988-95); 157, during the “substitution” period; and 153, during 
the last five-year period. 
Of the 407 individuals who answered the question on their current injecting behavior, 57% 
had injected in the last 30 days; current injection was more frequent in cases where the first 
injection was recent (19%, 44%, 64%, and 73% for the periods before 1987, 1987-1995, 
1996-2005, and 2006-2010, respectively). At the time of data collection, 16% of recent 
injection initiates had injected only once, 20% had injected 2 to 10 times, and 63% had 
injected more than 10 times (vs. 6%, 7%, and 87%, respectively, of users who were initiated 
into injection in 1987 or earlier; 7%, 4%, and 88%, respectively, for the 1988-95 group of 
injectors; and 5%, 4%, and 90%, respectively, for the 1996-2005 group, p < 0.001). 
 
3.2. Substance use prior to injection according to the period of first injection 
 
Heroin use before one’s first injection was reported by 84% to 90% of respondents, with no 
significant trend over time (Fig. 2). The use of cocaine and other stimulant drugs was more 
frequently reported in the 1988-95 group and increased according to the period of initiation (p 
< 0.001; 83% in the 2006-2010 group vs. 48% in the prior to 1987 group for cocaine). The 
fraction of injectors who had used amphetamines/ecstasy prior to injecting ranged from 38% 
in the prior to 1987 user group to 85% among recent initiates (2006-2010). Buprenorphine 
was used prior to injection by 3%, 15%, 46%, and 62% of respondents (p < 0.001) in groups 
that had initiated injection prior to 1987, in 1987-1995, in 1996-2005 or in 2006-2010, 
respectively. 
 
On average, the initiation of heroin use occurred at 19 years, with no variation across periods, 
whereas the reported age at the time of initiation for other substances was lower in the recent 
periods observed. Buprenorphine use in all groups was initiated at a later age than heroin. In 
the two last groups, i.e., starting from 1996, the first use of cocaine and amphetamines/ecstasy 
was reported to be earlier than the first use of heroin (Table 2).  
 
 
3.3. Characteristics and context surrounding the first injection 
 The median age at the time of first injection was slightly different depending on initiation 
period, with median ages of 18, 20, 19, and 21 years for groups that experienced the first 
injection prior to 1987, in 1987-1995, in 1996-2005, and in 2006-2010, respectively (Table 3), 
whereas 36%, 51%, 47% and 68% experienced their first injection at age 20 or older, 
respectively. The first injection and first use of the substance were simultaneous in 46% of 
respondents whose first injection occurred prior to 1987 and in 15% of respondents whose 
first injection was between 2006 and 2010. The time elapsed between the first use of the 
substance and actual injection was two years or more for 3% of the users who injected for the 
first time before 1987 and for 38% of those who started injecting in the most recent period. 
Heroin was the most commonly used substance during the first injection for all four groups, 
but the percentage of heroin as the first injected substance decreased over time from 76% 
prior to 1987 to 56% in the most recent period. Buprenorphine was not used for first 
injections prior to 1987 but was used by 6 to 10% of users in later periods without any 
increasing trend. Of the respondents who reported their first injection in 1996 or later, 16% 
injected cocaine (Figure 3). Most respondents who reported to the use of cocaine at first 
injection had previously used it (89%); this proportion was 80%, 78%, 70%, and 53% for 
buprenorphine, heroin, other substances, and other opiates, respectively. 
Most respondents reported having injected for the first time at home, in someone else’s place 
or in another private place. In total, 21% to 37% of first injections occurred in outdoor places, 
with little variation over time.  
The first injection was usually performed in the presence of other individuals, but 
administering the first injection alone was more common among recent injectors (30% for the 
2006-2010 user group vs. 3%, 9%, and 18% for the groups that first experience injection prior 
to 1987, in 1987-1995, and in 1996-2005). The percentage of first injections performed by 
another person decreased from 87% in the oldest group to 50% in the group injecting for the 
first time in 2006 or later (p < 0.001). 
 
4. Discussion  
 
The PrimInject study sought to identify the population most vulnerable to the risks of 
injection drug use by focusing on the first injection to find individuals with single episodes of 
injection, along with people who have begun long-term intravenous drug use. The PrimInject 
study was performed within the context of changing trends in substance use, drug policy, and 
drug supply. To our knowledge, PrimInject was the first study to describe the profiles of first 
injectors and the circumstances surrounding the first injection over time. This study was also 
the first study on this topic completed through an Internet survey. Another analysis of risky 
behaviors (e.g., sharing of syringes and equipment at first injection) will be presented in 
another paper under submission. 
 
The primary finding was that the first injection tends to occur at a later stage in the drug-using 
careers of individuals in the most recent period observed. This delay between substance use 
and injection of that substance is related to an earlier and more diversified use of substances. 
Heroin continues to play an important role in the initiation into injection, as its use preceded 
injection and the age at the time of initiation remained constant across various periods 
observed. In contrast, among recent initiates, the use of cocaine and other stimulants is more 
prominent. In this group, the use of stimulants preceded the use of heroin, and stimulants 
became for this generation the second most-injected substances during injection initiation. 
Although buprenorphine is widely used among young injected drug users, it is not frequently 
used in the initiation into injection and its use remains stable through time. Another difference 
between groups involved the greater number of individuals in the most recent period of 
initiation who performed their first injection alone. A large number of first injections took 
place outdoors in places with poor sanitary conditions.  
 
The age at the time of first injection was older among recent injection initiates, and the recent 
first injectors had a longer and more diverse history of substance abuse. The duration of 
substance abuse before the first injection increased from four to eight years in the oldest and 
youngest users, respectively. The increase in the number of substances used prior to the first 
injection may reflect changes in drug supplies (Cadet-Tairou et al., 2010), leading to a larger 
variety of drug use than that found in the 1980s; this change could explain the delay between 
substance use and initiation into injection.  
Despite the “generational” differences that were observed, heroin remains the most frequently 
injected substance during injection initiation, although the most common heroin format in 
France is powder, and the age at first use was the same across periods. Thus, heroin appears to 
be associated with injecting behavior, although observations suggest a long-term decrease in 
heroin use and injection practices (INSERM, 2010).  
Additionally, the PrimInject results underline the increasing use of cocaine and other 
stimulant drugs use over time in France (OFDT, 2012a). These findings reflect changes in the 
illegal drug market and confirm the increasing prevalence of stimulant drug use all over 
Europe (OEDT, 2012 ; EMCDDA et Europol, 2013). Early onset of the use of cocaine and 
other stimulant drugs and the increasing role of these drugs at first injection are particularly 
worrisome as cocaine injection behavior is demonstrated to be associated with higher drug use 
practices (Bourgois et Bruneau, 2000 ; Patrick et al., 2001 ; Tyndall et al., 2003 ; Roy et al., 
2013), which increases the probability of HIV and HCV transmission, especially during the 
sensitive injection initiation period. Given the wide availability of stimulant drugs in the 
European illegal drug market and their increasing role in drug abuse and maintenance 
treatment (Guichard et al., 2006 ; Carrieri et al., 2003), the risks associated with the use of 
cocaine and other stimulants (e.g., through equipment sharing) at the time of first injection 
deserve further investigation and reaffirm the need of new harm reduction tools for cocaine 
injectors.  
 
The PrimInject data show that BHD use has grown over time. The French system for drug 
substitution or maintenance treatment, which was established in 1996, differs from methadone 
clinics in other countries with regard to strictness, as there are more than 140,000 individuals 
who are currently treated with opioid substitution treatment in France, most of whom receive 
BHD (OFDT, 2012b). The wide availability of BHD from GPs fueled by flexible regulations 
for prescription and delivery has suddenly and completely changed the substitution experience 
for French users, thus exacerbating the risk of misuse of this substitution drug and diversion 
to the black market. French policy has shown positive outcomes, particularly the decrease of 
injection practices (Duburcq et al. 2000 ; Bilal et al., 2003 ; Carrieri et al., 2003; Costes et al., 
2004 ; INSERM, 2010), but researchers have observed that BHD is still widely used among 
French drug users, regardless of whether they are treated (Lalande et al., 2001; Escots et al., 
2004 ; Guichard, 2005 ; Langlois, 2011). BHD has also been shown to be injected among 
French users with injection rates ranging from 12% to 55% (Bry et al., 1998; Guichard et al., 
2001; Perdrieau et al., 1999; Duburcq et al., 2000; Fhima et al., 2001 ; Roux et al., 2008 ; 
Carrieri et al., 2003 ; Guichard et al., 2003), depending on how injection frequency was 
defined and the way that data were collected. Despite these practices, the results of Priminject 
show that BHD is not frequently used during the first injection, and its usage remains stable 
through time despite the large and increasing volume of individuals receiving BHD (20,000 
individuals in 1996, 70,000 in 2000, 90,000 in 2006, and 100,000 in 2009, including those 
using two generic forms introduced since 2006)1. This finding may have implications for the 
drug policy of countries that hesitate to introduce buprenorphine as maintenance treatment 
because they believe that diversion can facilitate initiation of injection. The data show that 
expanded access to buprenorphine and diversion to the black market does not imply that 
buprenorphine use spreads among youths, and buprenorphine does not appear to be a pathway 
to injection. However, the questionnaire in the present study only addressed the user’s 
practice and focused on the first injection, i.e., the main objective of the study; other behavior 
such as treatment-seeking or supply on the street market were not addressed. 
The percentage of new injectors injecting alone or without any help from another individual is 
higher among recent initiates. In total, 87% of the oldest group respondents reported receiving 
an injection from another person, which is consistent with earlier findings for long- term drug 
users in France (Vidal-Trecan et al., 2002). In recent studies, the percentage of individuals 
performing the first injection alone ranged from 8% to 26% (Goldsamt et al., 2010; Hadland 
et al., 2010; Lankenau et al., 2010; Novelli et al., 2005). One must consider the deep social 
transformations in France to understand these new patterns of initiation into injection. In a 
recent paper, Rhodes and colleagues (2011) analyzed the modes and practices of drug use, 
suggesting that initiation into injection is an identity-building process that must find meaning 
in the deepest transformations of “individualizing” postmodern societies before it can be 
negotiated and manifested in the everyday life of users. Moreover, in France, the spread of 
substitution drug treatments on the illegal drug market and the increased availability of 
substances that can be used in many different manners have contributed to the decline in 
injection rates. Simultaneously, the availability of clean syringes (sales of syringes and 
Steribox in pharmacies, on the Internet and from distributing machines) and Internet 
directions on how to inject may have led to the development of unassisted first injections and 
self-organizing for more private use. 
The hypothesis of more individualized drug use resulting from societal changes supports the 
relevance of recruiting through the Internet to access subgroups of hidden users not reached 
through other modes of recruitment (drug user networks, drug clinics, or recruitment in 
outdoor drug scenes). Until recently, the first injection was largely perceived as an event 
occurring in the social lives of users, performed by somebody else, usually involving other 
individuals and rarely done in isolation. 
 
                                                 
1 http://www.ofdt.fr/BDD_len/seristat/00028.xhtml 
To acquire information concerning users’ first injections, PrimInject reached a diverse 
population with respect to social status (45% were employed or university students), age 
(36% were 25 years old or younger), past and present drug use patterns, and frequency of 
drug use (43% were current injectors, 10% injected only once, and another 10% had injected 
less than 10 times). The purpose of this study was to portray the whole spectrum of current 
injection drug users, including those individuals who have a very short history of drug 
injection. Comparisons across different periods allow the understanding of the phenomena 
underlying injection behavior, but such comparisons should be made with caution because of 
the potential for participation bias. Participation was biased first by premature mortality 
resulting from AIDS and fatal overdoses among drug users who began injection during the 
1980s and 1990s. Second, individuals who have stopped using drugs may predominantly be 
found the eldest group, who are less likely to use the Internet and may not have seen the 
banners. Finally, it is likely that individuals from the eldest group who participated in the 
survey had a less severe addiction. This last factor must be kept in perspective because in the 
oldest group (who had a median age of 48 years), 81% were no longer injecting substances. 
Additionally, memory biases cannot be excluded for the oldest initiates.  
 
Conversely, recent injectors are more likely to use the Internet and attend social events or 
services where the PrimInject information was promoted. The main strength of the PrimInject 
study was that it reached a diverse sample of respondents rather than the older injection drug 
users described in surveys conducted in harm reduction services or healthcare facilities. The 
specific features identified for recent injectors may have been derived from participation bias, 
but they allow us to document a larger injecting population and changes in drug use patterns. 
This survey mode and its focus on the electronic scene may have biased recruitment with less 
success in reaching the most marginalized injectors, who may have had a different pattern of 
initiation. However, a sizeable proportion (one-third) of the sample was recruited through 
outreach teams, outside the internet channel. In such a hard-to-reach population, the 
Priminject study does not claim to be statistically representative; rather, it covers a spectrum 
of users broader than that usually described. Finally, the findings of the PrimInject study are 
consistent with observed trends in substance use and illegal drug markets in France (Cadet-
Tairou et al., 2010). 
 
 
 
5. Conclusion 
The results of the PrimInject study suggest that injecting is only one of many features of 
contemporary multiple substance use. The findings also brought to light the existence of a 
population that was exposed to injection outside of existing outreach programs and initiated 
injection when older, with a diversified experience of drug use in circumstances not reached 
by existing out-reach programs. These findings suggest the need to strengthen and diversify 
the range of preventive strategies to target groups and individuals at risk of injecting drugs, 
including a peer approach to reach new injectors injecting alone. In the context of HIV and 
HCV transmission among injecting drug users, the rising issue of cocaine use at first injection 
and the associated risks imply an urgent need for innovative programs to decrease the risk of 
blood-borne infections. Finally, given international drug policy debates regarding access to 
buprenorphine in countries requiring opioid maintenance treatments for HIV and the risk of 
misuse, the Priminject study shows that expanded access to buprenorphine does not facilitate 
the initiation of injection using this medication. 
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Table 1. Gender, age, education, and employment status at the time of data collection 
according to the period of initiation 
 Before harm 
reduction  
(before 1987) 
n = 71  
(16%) 
Free access to 
syringes 
(1988-1995) 
n = 68  
(15%) 
Substitution 
era 
(1996-2005) 
n = 157 
(35%) 
Recent 
period 
(2006-2010) 
n = 153 
(34%) 
 
 
 
p value 
Gender     ns 
Men  63% 59% 64% 67%  
Women 37% 41% 36% 33%  
Mean Age (SD), years 48 (5) 39 (4) 28 (6) 24 (6) *** 
Education      
< High school graduation   65% 63% 59% 48% * 
High school graduation   8% 16% 16% 26%  
> High school graduation   27% 21% 25% 26%  
Employment     *** 
Employed 48% 45% 33% 29%  
Unemployed 52% 51% 53% 39%  
Students  0% 4% 14% 32%  
Note: ***, p < 0.001; *, p < 0.05; ns, nonsignificant 
 
Table 2. Mean ages at initiation for the different substances used prior to injection according 
to the period of initiation.  
 
 
Before harm 
reduction 
(years, n) 
Free access 
to syringes 
(years, n) 
Substitution 
era 
(years, n) 
Recent 
period 
(years, n) p value 
Cocaine 20.8 (n = 63) 19.7 (n = 63) 17.7 (n = 139) 18.4 (n = 129) < 0.001 
Heroin 19.1 (n = 67) 18.8 (n = 62) 18.2 (n = 143) 19.1 (n = 128) 0.965 
Buprenorphine 33.1 (n = 42) 25.0 (n = 57) 20.7 (n = 130) 21.1 (n = 105) < 0.001 
Amphetamine/Ecstasy 21.3 (n = 55) 20.7 (n = 58) 17.2 (n = 137) 17.3 (n = 133) < 0.001 
Ketamine 30.0 (n = 10) 25.3 (n = 24) 19.5 (n = 78) 20.2 (n = 82) < 0.001 
 
Table 3. Summary table of respondent characteristics during their first injection and the 
circumstances of their first injection according to various periods 
 Before harm 
reduction  
(before 1987) 
n = 71 (16%) 
Free access to 
syringes 
(1988-1995) 
n = 68 (15%) 
Substitution era 
 
(1996-2005) 
n = 157 (35%) 
Recent period 
 
(2006-2010) 
n = 153 (34%) 
 
p value 
Age at first injection 
(median), years 
18 20 19 21  
Age at first injection      
Before 16 10% 6% 16% 7% p < 0.001 
16-17 23% 24% 15% 15%  
18-19 31% 19% 22% 10%  
20-24 28% 35% 30% 40%  
25 and older 8% 16% 17% 28%  
Time between first use and 
injection 
     
Never used before 46% 25% 19% 15% p < 0.001 
Among those who used it before 
injection 
     
Less than one year 64% 44% 40% 29%  
One or two years 30% 28% 34% 26%  
More than two years 6% 28% 26% 45%  
Place of first injection      
Home, hotel 79% 69% 63% 69% p = 0.312 
Squat, abandoned site 7% 15% 16% 10%  
Street, park, public toilets, etc. 3% 8% 12% 7%  
Van, car, tent 8% 7% 6% 9%  
   Other places 3% 1% 3% 5%  
Context of injection      
Alone 3% 9% 18% 30% p < 0.001 
Not alone, but injected by 
him/herself 
10% 21% 24% 20%  
Injected by another person 87% 71% 59% 50%  
 
 
 
 
  
Fig 1. Flow chart of data cleaning and exclusion criteria from the analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline  questionnaire 
(N = 1,884) 
Completed questionnaire (at least 
partially) 
(n = 1,318) 
 
 
Eligible for analysis 
(34%, N = 449) 
 
Excluded from the analysis (66%, n = 869) 
1- never injected (35%, n = 455) 
2- inconsistent responses (3%, n = 42) 
3- first injection section or date of first 
injection was incomplete (25%, n = 332) 
4- not living in France (3%, n = 40) 
Early drop out (before Q2) 
(30%, n = 566) 
Fig. 2. Substance used prior to injection (% per period) according to the period of initiation. 
 
 
 
 
 
Fig. 3. Injected substance at first injection (% per period) according to the period of initiation. 
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